share_log

Goldman Sachs Downgrades Novartis to Neutral, Raises Price Target to $121

Benzinga ·  Sep 5 18:49  · Ratings

Goldman Sachs analyst James Quigley downgrades Novartis (NYSE:NVS) from Buy to Neutral and raises the price target from $119 to $121.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment